Anti-Ebolavirus, GP (Clone EBOV-548) – Purified No Carrier Protein

Anti-Ebolavirus, GP (Clone EBOV-548) – Purified No Carrier Protein

Product No.: E172

- -
- -
Product No.E172
Clone
EBOV-548
Target
Ebolavirus (Pan)
Glycoprotein
Formats AvailableView All
Product Type
Recombinant Monoclonal Antibody
Alternate Names
Ebola, Ebolavirus
Isotype
Human IgG1
Applications
B
,
ELISA
,
EM
,
FA
,
N

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Ebola
Expression Host
HEK-293 Cells
Immunogen
Sequenced from PBMCs from a donor who had recovered from a naturally-occurring EBOV infection.
Product Concentration
≥1.0 mg/ml
Purity
≥90% monomer by analytical SEC and SDS-Page
Formulation
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
B,
ELISA,
EM,
FA,
N
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
EBOV-548 activity is directed against the glycan cap of the GP1 subunit of Zaire ebolavirus (EBOV) and Bundibugyo ebolavirus (BDBV) glycoprotein.
Background
Ebola virus is a member of the Filoviridae family that causes severe disease in humans with a mortality rate of 25-90%1. Three Ebola species are responsible for lethal outbreaks: Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Sudan ebolavirus (SUDV).

The Ebola virus envelope contains a single surface glycoprotein (GP) which is responsible for viral attachment to the host cell, endosomal entry, and membrane fusion1. GP is composed of two subunits, GP1 and GP2. GP1 has a heavily glycosylated mucin-like domain and a glycan cap. GP2 contains the internal fusion loop, transmembrane domain, and stalk. GP is the major target of neutralizing monoclonal antibody (mAb) and vaccine design against Ebola virus1,2,3,4.

EBOV-548 is a pan-EBOV-neutralizing mAb isolated from a survivor of the EBOV 2013-2016 outbreak2. Hybridomas were generated from human peripheral blood mononuclear cells. EBOV GP-reactive memory B cells were labeled with recombinant EBOV GP protein, purified by FACS, bulk expanded on NIH 3T3 cells, bulk fused with MFP-2 myeloma cells, and screened for neutralizing activity against live and/or recombinant EBOV, BDBV, and SUDV GP. EBOV-548 reacts to all three species GPs and neutralizes EBOV and BDBV. EBOV-548 recognizes intact but not cleaved GP.

EBOV-548 was identified in a study designed to develop a cooperative two-antibody cocktail with EBOV-5202,4. When paired, EBOV-548 and EBOV-520 have synergistic activity for GP binding and virus neutralization2. This is achieved mechanically. EBOV-548 binds to the glycan cap in a manner that destabilizes the GP trimer, displacing the β17-β18 loop. As a result, the glycan cap is pulled back, facilitating EBOV-520 binding and enhancing neutralization. The cooperative effect is dependent on EBOV-548 concentration. When administered together in vivo, EBOV-548 potentiates protection by EBOV-520 against SUDV, with 50% of mice surviving treatment, while only 10% survive with EBOV-520 alone.
Antigen Distribution
Ebola virus glycoprotein is a surface protein expressed on the virus envelope.
NCBI Gene Bank ID
UniProt.org
Research Area
Category A Pathogens
.
Infectious Disease
.
Viral
.
IVD Raw Material

References & Citations

1 Gilchuk P, Kuzmina N, Ilinykh PA, et al. Immunity. 49(2):363-374.e10. 2018.
2 Gilchuk P, Murin CD, Milligan JC, et al. Immunity. 52(2):388-403.e12. 2020.
3 Saphire EO, Aman MJ. Trends Microbiol. 24(9):684-686. 2016.
4 Murin CD, Gilchuk P, Ilinykh PA, et al. Cell Rep. 35(2):108984. 2021.
B
Indirect Elisa Protocol
EM
FA
N

Certificate of Analysis

Formats Available

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.